• Oseltamivir Acid: Influenza Neuraminidase Inhibitor in Actio

  2026-04-28

  Oseltamivir acid serves as a gold-standard influenza neuraminidase inhibitor with robust applications in both antiviral and oncology research. This article unpacks actionable workflows, resistance management strategies, and practical troubleshooting tips to maximize its translational impact.

• TGM1/3-Mediated Exo70 Transamidation Drives Metastasis via L

  2026-04-28

  Hou et al. (2024) uncover that transglutaminases TGM1 and TGM3 catalyze the transamidation of Exo70, a key exocyst component, promoting tumor metastasis. The study demonstrates that LKB1 suppresses this pro-metastatic modification via phosphorylation, identifying Exo70 transamidation as a tractable mechanism and potential therapeutic target in metastatic cancers characterized by LKB1 inactivation.

• Low-Dose Decitabine Restores Immune Tolerance in ITP via Tre

  2026-04-27

  This study demonstrates that low-dose decitabine can rebalance T-cell homeostasis in immune thrombocytopenia (ITP) by enhancing regulatory T cell (Treg) function and suppressing pro-inflammatory T cell subsets. These findings elucidate a mechanistic rationale for decitabine's durable efficacy in refractory ITP and refine its role as an immunomodulator beyond its established applications in hematopoietic malignancy research.

• Anlotinib Hydrochloride: Selective VEGFR2 Inhibition in Tumo

  2026-04-27

  This study rigorously characterizes anlotinib hydrochloride as a highly potent and selective inhibitor of VEGFR2, demonstrating strong anti-angiogenic effects both in vitro and in vivo. The findings highlight the compound’s superior efficacy and tolerability in preclinical cancer models, offering robust new avenues for targeted angiogenesis inhibition.

• IEM 1460: Optimizing AMPA Receptor Blocker Workflows in Neur

  2026-04-26

  IEM 1460 stands out as a highly selective AMPA receptor blocker, empowering researchers to dissect excitotoxicity, neuroprotection, and synaptic transmission with precision. Discover actionable protocol enhancements, troubleshooting insights, and evidence-driven workflow optimizations to maximize the reliability and impact of your AMPA receptor inhibition assays.

• Applied Workflows with EZ Cap™ Cy5 EGFP mRNA (5-moUTP) in mR

  2026-04-25

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) enables real-time tracking of both mRNA delivery and translation efficiency in a single experiment, thanks to dual Cy5 and EGFP labeling. This article details advanced experimental protocols, troubleshooting strategies, and the unique comparative advantages of this dual-fluorescent mRNA for gene delivery research.

• c-Myc tag Peptide: Mechanistic Depth in Transcriptional Cont

  2026-04-24

  Explore the mechanistic roles of the c-Myc tag Peptide in transcription factor regulation and immunoassay precision. This article offers a uniquely integrative analysis grounded in recent autophagy research, advancing understanding beyond standard workflows.

• Translating GSK-3 Inhibition: CHIR-99021 in Regenerative Sci

  2026-04-24

  Explore how CHIR-99021 (CT99021), a highly selective GSK-3 inhibitor, is catalyzing new paradigms in pluripotency maintenance, lineage specification, and translational modeling. This article bridges mechanistic discovery with actionable guidance, highlighting Wnt/β-catenin pathway modulation, integration with emerging organoid models, and strategic insights for advancing regenerative and disease-focused research.

• Dabigatran Etexilate: Precision Anticoagulation in Translati

  2026-04-23

  Explore how Dabigatran etexilate enables precision modulation of the coagulation cascade through selective thrombin inhibition. This article delivers a deep-dive into its biochemical mechanisms, assay optimization, and clinical implications, setting it apart from existing resources.

• FITC-Concanavalin A (ConA) Conjugate: Technical Use and QC G

  2026-04-23

  FITC-Concanavalin A (ConA) Conjugate enables researchers to detect and visualize α-D-glucose and α-D-mannose residues on cell surfaces using fluorescence-based methods. It is optimized for immunofluorescence, flow cytometry, and glycobiology assays, but should not be used outside carbohydrate-binding applications or beyond its defined stability conditions.

• Cediranib (AZD2171): Quantitative Angiogenesis Inhibition in

  2026-04-22

  Explore how Cediranib (AZD2171) enables quantitative, mechanism-driven assessment of angiogenesis inhibition for advanced cancer research. This article uniquely integrates in vitro drug response metrics with practical protocol parameters for deeper assay optimization.

• Temafloxacin: Fluoroquinolone Antibacterial Agent for Resear

  2026-04-22

  Temafloxacin stands out as a fluoroquinolone broad-spectrum antibacterial agent, offering potent inhibition across Gram-positive and Gram-negative bacteria, including challenging intracellular pathogens. This article details how to maximize Temafloxacin’s utility in experimental workflows, with protocol guidance, troubleshooting insights, and key learnings from synergistic antibacterial research.

• T7 RNA Polymerase: Precision Tools for Translational Innovat

  2026-04-21

  This thought-leadership article examines how T7 RNA Polymerase, a recombinant enzyme expressed in E. coli, underpins high-fidelity RNA synthesis for translational research. Integrating mechanistic insights with strategic guidance, it illustrates the enzyme’s value in areas from mitochondrial gene regulation to RNA vaccine production. The piece bridges recent breakthroughs in cardiac metabolism to the broader utility of precise in vitro transcription enzymes, benchmarking APExBIO’s offering within a competitive and rapidly evolving landscape.

• Chloroquine in Autophagy & Mineralization Research Workflows

  2026-04-21

  Chloroquine (N4-(7-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine) is a proven autophagy inhibitor and anti-inflammatory agent for malaria and rheumatoid arthritis research. Discover how to leverage its well-characterized mechanisms, with evidence-based protocols and troubleshooting strategies, for reproducible results in cellular mineralization and disease modeling.

• Autophagy-Mediated IRF3 Regulation and Its Impact on IFN Bal

  2026-04-20

  Wu et al. (2021) reveal that selective autophagy, mediated by CALCOCO2/NDP52 and regulated by deubiquitinase PSMD14, controls the stability of IRF3 to fine-tune type I interferon responses during viral infection. This mechanistic insight establishes a new paradigm for understanding transcription factor regulation in innate immunity and provides a foundation for related assay development.

451 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page